XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: The boxe study

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 1, 2013, Pages 257-264

  Rosati, Gerardo ^a   Avallone, Antonio ^b   Aprile, Giuseppe ^c   Butera, Alfredo ^d   Reggiardo, Giorgio ^e   Bilancia, Domenico ^a  

^a SAN CARLO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d S Giovanni di Dio Hospital   (Italy)

^e Biostatistic Unit Medi Service   (Italy)

Author keywords

Bevacizumab; Colorectal cancer; Elderly patients; Maintenance therapy; XELOX

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CAPECITABINE; OXALIPLATIN;

ADVANCED CANCER; AGED; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; EPISTAXIS; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INTENTION TO TREAT ANALYSIS; INTESTINE PERFORATION; LARYNX SPASM; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; SYNDROME DELINEATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; VOMITING; WOUND DEHISCENCE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; MALE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84872316412     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2004-x     Document Type: Article

References (32)

1. World Health Organization (2004) GBD 2001: deaths by age, sex and cause for the year. http://www.who.int/healthinfo/global-burden-disease/GBD-report- 2004update-part2.pdf. Accessed 29 Nov 2010
2. Ries LAG, Harkins D, Krapcho M, et al. (2003) Contents of the SEER cancer statistics review, 1975-2003. National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975-2003/. Accessed 3 Aug 2010
3. Simmonds PD, Best LY (1999) Should chemotherapy be used as a treatment of advanced colorectal carcinoma (ACC) in patients over 70 years age? Contra. Eur J Cancer 35:1640-1649
4. Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5:224-237
5. Kohne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P (2008) Chemotherapy in elderly patients with colorectal cancer. Oncologist 13:390-402
6. Folprecht G, Cunningham D, Ross P et al (2004) Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15:1330-1338
7. Goldberg RM, Tabah-Fisch I, Bleiberg H et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085-4091
8. Folprecht G, Seymour MT, Saltz L et al (2008) Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26:1443-1451
9. Sanoff HK, Bleiberg H, Goldberg RM (2007) Managing older patients with colorectal cancer. J Clin Oncol 25:1891-1897
10. Rosati G, Cordio S, Bordonaro R et al (2010) Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann Oncol 21:781-786
11. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
12. Saltz L, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
13. Kabbinavar F, Hurwitz H, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65
14. Kabbinavar F, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697-3705
15. Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842-1847
16. Cohn AL, Bekaii-Saab T, Bendell JC et al (2010) Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BriTE data on BV beyond progression (BBP). J Clin Oncol 28:15s Abstr 3596
17. Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BriTE). J Clin Oncol 26:5326-5334
18. Hochster HS, Hart LL, Ramanathan RK et al (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 26:3523-3529
19. Díaz-Rubio E, Gómez-España A, Massutí B et al (2012) First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 17:15-25
20. Scappaticci FA, Skillings JR, Scott N et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-1239
21. Kabbinavar FF, Hurwitz HI, Yi J et al (2009) Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27:199-205
22. Cassidy J, Saltz LB, Giantonio BJ et al (2010) Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 136:737-743
23. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
24. ICH website: http://www.ich.org
25. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376
26. Simon R (1989) Optimal two stage design for phase II clinical trials. Control Clin Trial 10:1-10
27. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-458
28. Kozloff M, Yood MU, Berlin J et al (2009) Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14:862-870
29. Hofheinz R, Grothe W, Tummes D et al. (2012) Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: mature results from a large community-based observational study. ASCO GI, Abstr 566
30. Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572
31. Vrdoljak E, Omrčen T, Boban M, Hrabar A (2011) Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer. Anticancer Drugs 22:191-197
32. Feliu J, Safont MJ, Salud A et al (2010) Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 102:1468-1473